IRADIMED CORP Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by IRADIMED CORPORATION on November 3, 2022. The filing serves to announce the company's financial results for the third quarter ended September 30, 2022, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the referenced press release (Exhibit 99.1) but are not included in the body of this 8-K filing.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 3, 2022) for actual Q3 2022 financial figures.
- Verify the company's status as an emerging growth company (indicated as not applicable in this filing).
- Confirm the trading symbol (IRMD) and exchange (NASDAQ Capital Market) for the common stock.
- Note that the financial data in this 8-K is not subject to Section 18 liabilities of the Exchange Act.